-
Eye injuries present a significant challenge to emergency personnel. Patient stress and coexisting periorbital findings can complicate any evaluation, and many of the signs of serious injury may be quite subtle. Because the majority of eye injuries present between 10 p.m. and 4 a.m. when ophthalmology consultation is not available immediately in most hospitals, a tremendous burden is placed on the emergency health care provider to identify and manage potential vision-threatening disorders. The following is a review of ocular trauma with a focus on clinical findings, their implications, and management.
-
-
Promising advances are being made on the microbicide front: U.S. funding appears imminent for microbicide research and development, a new corporate partnership has been struck with an international research group to step up testing of antiviral AIDS gels, and a number of potential candidates are moving through the research pipeline.
-
What is the policy for providing emergency contraception (EC) at your facility? About 81% of respondents to the 2004 Contraceptive Technology Update Contraception Survey say their facilities prescribe EC on site and provide emergency contraceptive pills (ECPs) at any time, which continues a trend of strong support for the method.
-
Should a woman who is obese and continues to gain weight on Depo-Provera [depot medroxyprogesterone acetate (DMPA), Pfizer, New York City] be allowed to continue its use if she so desires? Are providers contributing to the health risk of obesity by allowing a woman to do so?
-
Post hoc analysis of 3 large multicenter trials of patients with acute coronary syndromes demonstrates a strong association between transfusion and mortality.
-
This multicenter prospective observational study reveals that transfusion practice in the critically ill has not changed in the past decade. 44% of ICU patients receive transfusions, and transfusions continue to be associated with worse clinical outcomes.
-
The Infection Risk of Acid-Suppressing Drugs; Is Rosuvastatin As Safe As Other Statins?; Which Estrogen Preparation is the Safest?; FDA Actions.
-
-
